ashihla Weekly Update MultiBriefs
Contact Us
Media Kit

Browse Categories

Browse by Date

Search past issues
Search products and services

HT-2 samples were shipped on Tuesday, September 10th. The result submission deadline for the HT-2 survey is Friday, October 18th. Click here to view the PT shipment and result submission schedule for 2019.


A major obstacle in kidney transplantation for primary focal segmental glomerulosclerosis (FSGS) is the risk of disease recurrence. Recurrent FSGS affects up to 60% of first kidney grafts and exceeds 80% in patients who have lost their first graft due to recurrent FSGS.

source: Frontiers in Immunology

Dialysis is the first procedure to partially replace renal function in end-stage renal diseases, despite several adverse side effects, such as infections. The primary aim of this study was to evaluate the levels of immune...

source: PubMed

Lung transplant is a definitive treatment for several end-stage lung diseases. However, the high incidence of allograft rejection limits the overall survival following lung transplantation.

source: Human Immunology

The role of donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized over the past 20 years. During this time, there has been growing...

source: Human Immunology

Angiotensin II type I receptor (AT1R) is a critical player in regulating vasoconstriction, blood pressure, sodium retention. Even though AT1R has limited polymorphism, AT1R antibodies have been detected in several diseases.

source: Human Immunology


Powered by MultiBriefs
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063

Subscribe to ASHI Insights

*First Name:
*Last Name:
Street Address:
State / Province:
Zip / Postal Code:
Are you a member of ASHIHLA? Yes   No
Privacy Policy